Xanthohumol from Hop: Hope for cancer prevention and treatment

Area of Science:

• Natural Products Chemistry
• Oncology
• Molecular Biology

Background:

• Cancer presents a significant global health challenge with high mortality and reduced quality of life.
• Current cancer treatments often lack efficacy, are costly, and cause adverse side effects, necessitating novel therapeutic strategies.
• Drug resistance, poor specificity, and low efficacy of existing drugs highlight the need for alternative cancer prevention and treatment approaches.

Purpose of the Study:

• To review the anti-cancer properties of Xanthohumol (XN), a prenylated chalcone found in hops (Humulus lupulus).
• To explore the diverse molecular targets and signaling pathways modulated by XN in cancer cells.
• To assess the therapeutic potential of XN as a multi-targeted anti-cancer agent.

Main Methods:

• Literature review of studies investigating Xanthohumol's anti-cancer activities.
• Analysis of XN's effects on cancer cell growth and proliferation.
• Examination of XN's modulation of key signaling pathways and proteins involved in cancer progression.

Main Results:

• Xanthohumol (XN) demonstrated inhibitory effects on cancer cell growth and proliferation.
• XN modulates multiple critical signaling pathways, including Akt, AMPK, ERK, IGFBP2, NF-κB, and STAT3.
• XN influences various proteins and markers such as Notch1, caspases, MMPs, Bcl-2, cyclin D1, oxidative stress markers, tumor-suppressor proteins, and miRNAs.

Conclusions:

• Xanthohumol (XN) exhibits substantial therapeutic potential against a range of cancers.
• XN acts as a multi-targeted agent, offering a promising strategy for cancer treatment.
• The findings suggest XN could be developed into an effective anti-cancer therapy with potentially minimal adverse effects.